Spotlight On ATTR-CM
Welcome to Spotlight On ATTR-CM, your go-to source for the latest research, diagnostic advancements, and therapeutic strategies in transthyretin amyloid cardiomyopathy (ATTR-CM). Join leading cardiologists and researchers as they share their insights on this intricate condition to enhance patient care and outcomes.
Recognizing ATTR-CA in Cardioembolic Stroke: Emerging Diagnostic Clues
Heart MattersRecognizing ATTR-CA in Cardioembolic Stroke: Emerging Diagnostic Clues
Exploring Deeper Silencing in Transthyretin Amyloidosis
AudioAbstractsExploring Deeper Silencing in Transthyretin Amyloidosis
Ryan Quigley
How Symptoms Shape Caregiver Burden in ATTR-CM
AudioAbstractsHow Symptoms Shape Caregiver Burden in ATTR-CM
Ryan Quigley
Ronald Witteles, MD
Assessing Stroke Risk in ATTR-CM with Atrial Mechanics
Heart MattersAssessing Stroke Risk in ATTR-CM with Atrial Mechanics
The Limits of Traditional AFib Prediction Models in ATTR-CA
Heart MattersThe Limits of Traditional AFib Prediction Models in ATTR-CA
Quality of Life Conversations in ATTR-CM Care
Heart MattersQuality of Life Conversations in ATTR-CM Care
Kevin S. Shah, MD
Supporting Patients With ATTR-CM: Preserving Function and Quality of Life
Heart MattersSupporting Patients With ATTR-CM: Preserving Function and Quality of Life
Joban Vaishnav, MD
Counseling Patients on Disease Progression in ATTR-CM
Heart MattersCounseling Patients on Disease Progression in ATTR-CM
Joban Vaishnav, MD
Rethinking Thromboembolic Risk in ATTR-CM Care
Heart MattersRethinking Thromboembolic Risk in ATTR-CM Care
Silencers and Stabilizers in ATTR-CM: Challenging Assumptions
Heart MattersSilencers and Stabilizers in ATTR-CM: Challenging Assumptions
- advertisement
Adverse-Effect Management in ATTR-CM: Tolerance, Monitoring, and Continuity
Spotlight On ATTR-CMAdverse-Effect Management in ATTR-CM: Tolerance, Monitoring, and Continuity
Advanced ATTR-CM Management: Narrow Reserve, Narrow Margin
Spotlight On ATTR-CMAdvanced ATTR-CM Management: Narrow Reserve, Narrow Margin
Multidisciplinary ATTR-CM Care: The Importance of Coordinated Care
Spotlight On ATTR-CMMultidisciplinary ATTR-CM Care: The Importance of Coordinated Care
ATTR-CM Implementation Evidence: Real-World Care Provides the Missing Context
Spotlight On ATTR-CMATTR-CM Implementation Evidence: Real-World Care Provides the Missing Context
Understanding Conflicting ATTR-CM Evidence: The Influence of Study Population and Study Design
Spotlight On ATTR-CMUnderstanding Conflicting ATTR-CM Evidence: The Influence of Study Population and Study Design
ATTR-CM Guidance: Principles of Noninvasive Diagnosis
Spotlight On ATTR-CMATTR-CM Guidance: Principles of Noninvasive Diagnosis
Landmark ATTR-CM Evidence: Slowing Progression, Not Reversing It
Spotlight On ATTR-CMLandmark ATTR-CM Evidence: Slowing Progression, Not Reversing It
FDA Labels in ATTR-CM: Approval Is Bounded by Phenotype
Spotlight On ATTR-CMFDA Labels in ATTR-CM: Approval Is Bounded by Phenotype
Refractory ATTR-CM: Persistent Burden Is Not Always Drug Failure
Spotlight On ATTR-CMRefractory ATTR-CM: Persistent Burden Is Not Always Drug Failure
Acoramidis in Pregnancy: Sparse Human Data in ATTR-CM
Spotlight On ATTR-CMAcoramidis in Pregnancy: Sparse Human Data in ATTR-CM
Acoramidis in ATTR-CM: Targeted Stabilization, Not Reversal
Spotlight On ATTR-CMAcoramidis in ATTR-CM: Targeted Stabilization, Not Reversal
Ongoing Trials in ATTR-CM: What Current Study Design May Clarify
Spotlight On ATTR-CMOngoing Trials in ATTR-CM: What Current Study Design May Clarify
- advertisement